TY - JOUR
T1 - Combined dementia-risk biomarkers in Parkinson's disease
T2 - A prospective longitudinal study
AU - Compta, Yaroslau
AU - Pereira, Joana B.
AU - Ríos, Jose
AU - Ibarretxe-Bilbao, Naroa
AU - Junqué, Carme
AU - Bargalló, Núria
AU - Cámara, Ana
AU - Buongiorno, Mariateresa
AU - Fernández, Manel
AU - Pont-Sunyer, Claustre
AU - Martí, Maria J.
N1 - Funding Information:
The authors are most grateful to all the patients who participated in this study and acknowledge the help of Dr. E. Tolosa, Dr. F. Valldeoriola and Dr. E. Muñoz (Movement Disorders Unit, Hospital Clínic de Barcelona, Catalonia, Spain; recruitment phase), Mrs. A Martín, Mr. C. Garrido, Mr. M. Fabregat and Mr. S. Sotes (MRI Unit, Hospital Clínic de Barcelona, Catalonia, Spain; MRI acquisition), Dr E. Gelpí (Banc of Neurological Tissue, Biobanc, IDIBAPS/Hospital Clínic, Barcelona, Catalonia, Spain; neuropathological additional data), and Dr. F. Lomeña (Nuclear Medicine Department, Hospital Clínic, Barcelona, Catalonia, Spain), Dr. I. Ramirez (Barnatron, Cetir, Esplugues, Catalonia, Spain), Dr. J.R. Garzón (Unitat PET, Cetir, Esplugues, Catalonia, Spain), Dr. J. Pavía, Dr. Y. Fernandez (Centre of Experimental Molecular Imaging, Cetir, Esplugues, Catalonia, Spain), Dr. V. Kepe and Dr. JR Barrio (Department of Molecular Pharmacology, UCLA, CA, USA) (FDDNP-PET image acquisition, reconstruction and interpretation). This study was funded through “Fundació La Marató de TV-3” (N-2006-TV060510).
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2013/8
Y1 - 2013/8
N2 - Neuropsychological (mostly posterior-cortical) deficits, quantitative magnetic resonance imaging (MRI) atrophy patterns, and low cerebrospinal fluid (CSF) levels of amyloid-β have been separately related to worsening cognition in Parkinson's disease (PD). However, these biomarkers have not been longitudinally assessed in combination as PD-dementia predictors. In this prospective longitudinal study, 27 non-demented PD patients underwent CSF, neuropsychological and 3-Tbrain-MRI studies at baseline and were re-assessed 18 months later in terms of progression to dementia (primary outcome) and longitudinal neuropsychological and cortical thickness changes (secondary outcomes). At follow-up 11 patients (41%) had progressed to dementia. Lower CSF amyloid-β, worse verbal learning, semantic fluency and visuoperceptual scores, and thinner superior-frontal/anterior cingulate and precentral regions were significant baseline dementia predictors in binary logistic regressions as quantitative and/or dichotomised traits. All participants without baseline biomarker abnormalities remained non-demented whereas all with abnormalities in each biomarker type progressed to dementia, with intermediate risk for those showing abnormalities in a single to two biomarker types (p=0.006). Both the dementia-outcome and low baseline CSF amyloid-β were prospectively associated with limbic and posterior-cortical neuropsychological decline and frontal, limbic and posterior-cortical thinning from baseline to follow-up. These findings suggest that the combination of CSF amyloid-β, neuropsychological and cortical thickness biomarkers might provide a basis for dementia-risk stratification and progression monitoring in PD.
AB - Neuropsychological (mostly posterior-cortical) deficits, quantitative magnetic resonance imaging (MRI) atrophy patterns, and low cerebrospinal fluid (CSF) levels of amyloid-β have been separately related to worsening cognition in Parkinson's disease (PD). However, these biomarkers have not been longitudinally assessed in combination as PD-dementia predictors. In this prospective longitudinal study, 27 non-demented PD patients underwent CSF, neuropsychological and 3-Tbrain-MRI studies at baseline and were re-assessed 18 months later in terms of progression to dementia (primary outcome) and longitudinal neuropsychological and cortical thickness changes (secondary outcomes). At follow-up 11 patients (41%) had progressed to dementia. Lower CSF amyloid-β, worse verbal learning, semantic fluency and visuoperceptual scores, and thinner superior-frontal/anterior cingulate and precentral regions were significant baseline dementia predictors in binary logistic regressions as quantitative and/or dichotomised traits. All participants without baseline biomarker abnormalities remained non-demented whereas all with abnormalities in each biomarker type progressed to dementia, with intermediate risk for those showing abnormalities in a single to two biomarker types (p=0.006). Both the dementia-outcome and low baseline CSF amyloid-β were prospectively associated with limbic and posterior-cortical neuropsychological decline and frontal, limbic and posterior-cortical thinning from baseline to follow-up. These findings suggest that the combination of CSF amyloid-β, neuropsychological and cortical thickness biomarkers might provide a basis for dementia-risk stratification and progression monitoring in PD.
KW - Amyloid-β
KW - Cerebrospinal fluid
KW - Cortical thickness
KW - Dementia predictors
KW - Longitudinal analysis
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=84879411933&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2013.03.009
DO - 10.1016/j.parkreldis.2013.03.009
M3 - Artículo
C2 - 23643469
AN - SCOPUS:84879411933
VL - 19
SP - 717
EP - 724
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
SN - 1353-8020
IS - 8
ER -